investordatabase.org

Proto Axiom

protoaxiom.com Direct investor

Proto Axiom is an Australian biotechnology company builder and private holding company with permanent capital that forms and funds companies from Australian science. It invests through milestone-gated tranches and holds founding-investor and venture stakes in its portfolio companies.

Proto Axiom is a venture studio headquartered in North Sydney, Australia, founded in 2021. It invests directly in companies, from pre-seed to Series A, in therapeutics, radiopharmaceuticals, diagnostics and Women's health. 11 portfolio companies, as it reports.

“We create and operate biotechnology companies from Australian science. We are not a fund allocating across other people's companies.”

— Proto Axiom, own website
Layer
Direct investor
Type
Venture studio
Stage
Pre-seed – Series A
Headquarters
North Sydney, Australia
Invests in
Australia, global
Sectors
Therapeutics, Radiopharmaceuticals, Diagnostics, Women's health, Fertility, Bioprocessing, AgBio, Digital health
Founded
2021
Portfolio
11 companies

Team, as Proto Axiom publishes it

  • Anthony Liveris Chief Executive Officer
  • Lindsay Wu, PhD Chief Science Officer
  • Hugh McGonagle Chief Operating Officer
  • Tony Haddad Operating Partner
  • John Roach Head of Finance
  • Laura Wimberger, PhD Investment Associate
  • Richard Wang, PhD Science Analyst
  • Marina Naidion Business Manager
  • Nicholas Hunt, PhD Entrepreneur in Residence
  • Gavin MacLaren Chairman
  • Kathy Connell, GAICD Non-Executive Director
  • Tom Harley Non-Executive Director

Names and roles exactly as listed on protoaxiom.com. Nothing else about these people is recorded.

Where this comes from

Every fact above was read from a page Proto Axiom publishes itself. Nothing is taken from third-party databases. Investment activity (deals, co-investors) is not yet recorded.

Is this record wrong or stale? Report a mistake — it reaches us directly, no email address to look up.

Record 15413 · added 2026-10-20 · link last verified 2026-10-21 · confidence high

Similar investors

Listed under